European Industry Urges State Aid Changes To Allow COVID Recovery
Medicines For Europe Calls For Five-Year Temporary Relief To Permit Investment
• By David Wallace
Generate a summary of this article
Listen to this article
A five-year period of temporary relief from EU state aid rules should be introduced for countries willing to invest in API and medicine production, Medicines for Europe has urged, insisting that current restrictions do not allow the investment necessary to bolster the supply chain in the wake of COVID-19.
Medicines for Europe is calling for a five-year temporary relief from state aid rules to allow sufficient investment in the supply chain • Source: Alamy
Changes to EU state aid rules are necessary so that European countries can invest sufficiently in active pharmaceutical ingredient and medicine production, in order to strengthen the supply chain as the region recovers from the COVID-19 pandemic, off-patent industry association Medicines for Europe has urged.
[Sidebar#GB151351]
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.